Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase IIα and prognosis

Brustmann, Hermann

doi:10.1016/j.ygyno.2004.07.040

Cited by 28 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, it is noteworthy that TOPO-IIa is involved in several biological pathways of tumour aggressiveness: for instance, TOPO-IIa is correlated with the proliferation associated marker ki67 (Costa et al, 2000), the Vascular Endothelial Growth Factor Figure 3 Overall survival curves in ovarian cancer patients according to the status of TOPO-IIa. (Brustmann, 2004), and also with the product of erbB2/neu oncogene (Mano et al, 2004;Hicks et al, 2005); moreover, TOPO-IIa expression seems to be regulated by p53 oncosuppressor gene (Sandri et al, 1996), whose mutations are differentially involved in platinum vs paclitaxel sensitivity in ovarian cancer (Ferrandina et al, 1999;Lavarino et al, 2000). Interestingly enough, the unfavourable prognostic role of high TOPO-IIa content was documented only in the subgroup of platinum-resistant ovarian cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…While these observations favour the possibility that TOPO-IIa overexpression could identify ovarian cancer patients with better clinical outcome, on the other hand other authors suggested that it might serve as a marker of aggressive features and poor prognosis (Gotlieb et al, 2001;Brustmann 2004;Mano et al, 2004). The discrepancies across earlier studies might be explained by the different design, the methodologies of TOPO-IIa assessment, the small sample series, and the lack of data on salvage treatment (Cornarotti et al, 1996;Gotlieb et al, 2001;Brustmann 2004;Mano et al, 2004): indeed, it has to be taken into account that the analysis of the potential prognostic impact of TOPO-IIa might be someway influenced by the role played by the same target as predictor of sensitivity to TOPO-IIa inhibitory drugs, often used in the salvage setting.…”

mentioning

confidence: 99%

“…To our knowledge, very few data about the role of TOPO-IIa expression in predicting clinical outcome of ovarian cancer patients is currently available (Gotlieb et al, 2001;Brustmann 2004).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients

Ferrandina

Petrillo

Carbone³

et al. 2008

Br J Cancer

View full text Add to dashboard Cite

To our knowledge, very few data about the role of Topoisomerase IIa (TOPO-IIa), an enzyme involved in critical steps of tumour cell proliferation and chemoresistance are currently available in ovarian cancer patients. The aim of this study was to investigate the prognostic value of TOPO-IIa expression in a large, single institution series of 96 primary untreated advanced ovarian cancer patients admitted to the Gynecologic Oncology Unit, Catholic University of Campobasso and Rome. Immunohistochemistry was carried out by using the MoAb anti-human TOPO-IIa antibody (clone Ki-S1). TOPO-IIa immunoreaction was observed in 70 out of 96 cases (72.9%), and the percentages of positively stained cells ranged between 1 and 83% (median ¼ 10%). There was no association with clinico-pathological parameters. During the follow up period, progression and death of disease were observed in 76 (79.2%) and 45 (46.9%) cases. A statistically significant direct association between the percentages of positively immunostained tumour cells and the relative risk of death was observed (w 2 ¼ 6.6, P-value ¼ 0.0101). In multivariate analysis, only platinum resistance, advanced stage of disease and high levels of TOPO-IIa expression retained an independent negative prognostic role for OS. The unfavourable role of high TOPO-IIa expression was maintained only in the subgroup of platinum resistant recurrent ovarian cancer patients, be TOPO-IIa expression evaluated as continuous variable (w 2 ¼ 5.1, P-value ¼ 0.024), or by means of the defined cutoff point. Our study suggests that the assessment of TOPO-IIa could be helpful to identify poor prognosis platinum-resistant ovarian cancer patients, potentially candidates to investigational agents.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients

Ferrandina

Petrillo

Carbone³

et al. 2008

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…4.1 VEGF expression in epithelial ovarian cancer VEGF expression in epithelial ovarian cancer has been intensively examined (Wong et al, 2003;Yamamoto et al, 1997;Brustmann, 2004;Mabuchi et al, 2010b). It has been generally accepted that VEGF expression is greater in ovarian cancers than in normal ovarian tissue or benign ovarian neoplasm.…”

Section: Role Of Vegf In Epithelial Ovarian Cancer: Preclinical Findingsmentioning

confidence: 99%

“…It has been generally accepted that VEGF expression is greater in ovarian cancers than in normal ovarian tissue or benign ovarian neoplasm. According to previous reports, in which common histological www.intechopen.com subtypes such as serous adenocarcinoma or endometrioid adenocarcinoma were investigated, the expression rate of VEGF was approximately 90% (Wong et al, 2003;Yamamoto et al, 1997;Brustmann, 2004). In a recent report about clear cell carcinoma of the ovary, strong VEGF expression was observed in 86% of cases (Mabuchi et al, 2010b).…”

Section: Role Of Vegf In Epithelial Ovarian Cancer: Preclinical Findingsmentioning

confidence: 99%

VEGF Targeting Agents in Ovarian Cancer

Mabuchi¹,

Wakabayashi²,

Kimura³

2012

Ovarian Cancer - Basic Science Perspective

View full text Add to dashboard Cite

Prognostic significance of β‐catenin and topoisomerase IIα in de novo acute myeloid leukemia

et al. 2009

View full text Add to dashboard Cite

The Wnt/b-catenin signaling is important for controlling self-renewal of hematopoietic stem cells and its constitutive activation has recently been documented in a significant proportion of acute myeloid leukemia (AML) cases. Topoisomerase IIa (Topo IIa) is a marker of cell proliferation and a crucial target for anthracycline cytotoxicity, the mainstay of management employed in AML. We retrospectively investigated the prognostic roles of b-catenin and topo IIa in a cohort of 59 patients with newly diagnosed AML by immunohistochemistry. Aberrant b-catenin expression was demonstrated in 13 patients (22%), and it was more likely to occur in those with unfavorable karyotypes. Advanced age and poor performance status adversely influenced the achievement of complete remission, while neither aberrant b-catenin expression nor enhanced topo IIa activity did. On multivariate survival analysis, four factors independently predicted a shortened overall survival: aberrant b-catenin expression, high topo IIa activity, poor-risk cytogenetics, and presence of at least one comorbidity factor. Our results suggest that both b-catenin and topo IIa independently predicted an adverse prognosis and might serve as new markers for risk stratification in AML patients. Am. J.

show abstract

Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase IIα and prognosis

Cited by 28 publications

References 21 publications

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients

VEGF Targeting Agents in Ovarian Cancer

Prognostic significance of β‐catenin and topoisomerase IIα in de novo acute myeloid leukemia

Contact Info

Product

Resources

About